NEW YORK June 19 2017 PRNewswire Immune Pharmaceuticals Inc. NASDAQ IMNP the "Company" announced today that on June 15 2017 the Company received written notice from the Nasdaq that the Company has regained compliance with Listing Rule 5250c1 and...
↧